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Quantification of ligand density and stoichiometry on the surface of liposomes 
using single-molecule fluorescence imaging 
Abstract 
Despite the longstanding existence of liposome technology in drug delivery applications, there have been 
no ligand-directed liposome formulations approved for clinical use to date. This lack of translation is due 
to several factors, one of which is the absence of molecular tools for the robust quantification of ligand 
density on the surface of liposomes. We report here for the first time the quantification of proteins 
attached to the surface of small unilamellar liposomes using single-molecule fluorescence imaging. 
Liposomes were surface-functionalized with fluorescently labeled human proteins previously validated to 
target the cancer cell surface biomarkers plasminogen activator inhibitor-2 (PAI-2) and trastuzumab (TZ, 
Herceptin®). These protein-conjugated liposomes were visualized using a custom-built wide-field 
fluorescence microscope with single-molecule sensitivity. By counting the photobleaching steps of the 
fluorescently labeled proteins, we calculated the number of attached proteins per liposome, which was 11 
± 4 proteins for single-ligand liposomes. Imaging of dual-ligand liposomes revealed stoichiometries of the 
two attached proteins in accordance with the molar ratios of protein added during preparation. 
Preparation of PAI-2/TZ dual-ligand liposomes via two different methods revealed that the post-insertion 
method generated liposomes with a more equal representation of the two differently sized proteins, 
demonstrating the ability of this preparation method to enable better control of liposome protein 
densities. We conclude that the single-molecule imaging method presented here is an accurate and 
reliable quantification tool for determining ligand density and stoichiometry on the surface of liposomes. 
This method has the potential to allow for comprehensive characterization of novel ligand-directed 
liposomes that should facilitate the translation of these nanotherapies through to the clinic. 
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Despite the longstanding existence of liposome technology in drug delivery applications, 25 
there have been no ligand-directed liposome formulations approved for clinical use to date. 26 
This lack of translation is due to several factors, one of which is the absence of molecular 27 
tools available for the robust quantification of ligand density on the surface of liposomes. We 28 
report here for the first time the quantification of proteins attached to the surface of small 29 
unilamellar liposomes using single-molecule fluorescence imaging. Liposomes were surface-30 
functionalized with fluorescently-labeled human proteins previously validated to target 31 
cancer cell surface biomarkers: plasminogen activator inhibitor-2 (PAI-2) and trastuzumab 32 
(TZ, Herceptin®). These protein-conjugated liposomes were then visualized using a custom-33 
built wide-field fluorescence microscope with single-molecule sensitivity. By counting the 34 
photobleaching steps of the fluorescently-labeled proteins, we calculated the number of 35 
attached proteins per liposome, which was in the range of 1-11 proteins for single-ligand 36 
liposomes. Imaging of dual-ligand liposomes revealed stoichiometries of the two attached 37 
proteins in accordance with the molar ratios of protein added during preparation. Preparation 38 
of PAI-2/TZ dual-ligand liposomes via two different methods revealed that the post-insertion 39 
method generated liposomes with a more equal representation of the two differently-sized 40 
proteins, demonstrating the ability of this preparation method to control protein densities. We 41 
conclude that the single-molecule imaging method presented here is an accurate and reliable 42 
quantification tool for determining ligand stoichiometry on the surface of liposomes. This 43 
method has the potential to allow for comprehensive characterization of novel ligand-directed 44 
liposomes that should facilitate the translation of these nanotherapies through to the clinic. 45 
 46 
Keywords: functionalized liposomes, ligand quantification, single-molecule fluorescence 47 
microscopy, molecular characterization 48 
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1. Introduction 49 
Liposomes have been utilized as delivery systems for drugs and other molecules in vivo for 50 
several decades [1]. In the context of cancer therapy, liposome-based drug formulations have 51 
demonstrated distinct advantages over free drug, including the improved solubility of 52 
encapsulated drugs, increased in vivo circulation time, reduction in systemic toxicity of the 53 
drug and increased delivery to the tumor site [2]. The superior activity of drug-loaded 54 
liposomes relies on a multi-step process involving both passive and active targeting 55 
mechanisms. Passive targeting is primarily mediated by the enhanced permeability and 56 
retention effect [3]. This phenomenon is characterized by the extravasation and retention of 57 
small particles into the tumor interstitial space due to highly porous tumor vasculature and 58 
poor lymphatic drainage from the tumor site [4]. The prolonged retention of liposomes in the 59 
vicinity of the tumor increases the local drug concentration, either when drug released from 60 
the liposomes is taken up by tumor cells, or when liposomes containing the drug are 61 
internalized by tumor cells [5]. Passive targeting, therefore, reduces off-target effects by 62 
preferentially accumulating drug-loaded liposomes in the vicinity of the tumor while 63 
reducing the exposure of normal cells to the cytotoxic drug. 64 
Active targeting is achieved via conjugation of one or more ligands to the liposome 65 
surface, with that ligand binding to a target receptor(s) expressed on the tumor cell surface 66 
[6]. Following liposome extravasation into the tumor interstitial space, subsequent ligand-67 
directed surface binding and internalization (usually via receptor-mediated endocytosis) 68 
promotes liposome and drug entry into specific cell types [7]. As actively targeted liposome 69 
formulations combine both passive and active drug-delivery mechanisms, actively targeted 70 
liposomes can show superior drug delivery to non-targeted liposomes [8]. Liposomes with 71 
one or more targeting moieties that facilitate active uptake into cells are termed ligand-72 
directed liposomes. In the context of cancer therapy, the development of dual-ligand-directed 73 
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liposomes that can actively target more than one tumor cell subtype and/or stromal cell 74 
populations may help overcome therapeutic limitations caused by the intratumoral 75 
heterogeneity of cancer [9, 10].  76 
Despite extensive research and development of nanoparticle-based therapeutics, all 77 
clinically approved liposome formulations are non-ligand-directed, with efficacies relying 78 
solely on passive targeting and accumulation [11]. A comprehensive list can be found 79 
elsewhere [12]. Active targeting strategies using liposomes have been extensively explored in 80 
the preclinical setting, particularly liposomes targeting tumor-associated receptors, with many 81 
reported formulations demonstrating improved efficacy over non-ligand-directed liposomes 82 
[13, 14]. Given the general movement in the field towards actively targeted nanotherapeutics, 83 
the lack of translation of ligand-directed liposome formulations into clinical practice is 84 
somewhat surprising [15]. Previous reviews have identified some of the likely reasons for this 85 
phenomenon, ranging from methodological difficulties involved in the large-scale preparation 86 
of ligand-directed liposomes, to the limitations of evaluating their efficacy in preclinical 87 
models that fail to adequately recapitulate human tumors [16]. For example, once liposomes 88 
are administered intravenously, nonspecific interactions of liposomes with a range of plasma 89 
proteins may result in the formation of a protein ‘corona’ at the liposome surface, effectively 90 
shielding liposome-bound targeting ligands from interacting with their target receptors and 91 
therefore negating their intended tumor cell targeting effect [17]. 92 
The absence of molecular tools for the robust characterization of complex liposomes 93 
may also be contributing to the lack of clinically approved ligand-directed liposomes. 94 
Specifically, no methodology exists to quantify the number of ligands covalently bound to the 95 
surface of liposomes. Estimation of ligand conjugation is possible based on preparation 96 
parameters, but direct measurement of total surface-bound protein using standard 97 
biochemical assays have their limitations. For example, measurement of surface-bound 98 
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protein in an actively targeted liposome formulation using colorimetric biochemical methods 99 
is challenging due to phospholipid interference in the measurement of very low protein 100 
concentrations [18]. While such measurements could potentially quantify the total protein in 101 
a sample, they cannot provide information about the number of ligands per liposome in a 102 
formulation. Flow cytometric methods that detect the insertion of fluorescently labeled 103 
micelles into liposomes as a proxy for successful liposome functionalization have been 104 
reported, but are indirect and semi-quantitative [19]. The lack of quantitative methodology 105 
poses a particular challenge for the development of liposomes with more than one surface-106 
bound ligand, since the determination of ligand stoichiometry is important for controlling for 107 
batch-to-batch variability in the laboratory and for clinical production. The absence of 108 
rigorous quantification protocols hinders high-quality large-scale manufacturing of ligand-109 
directed liposome formulations, which may introduce regulatory barriers and slow down their 110 
introduction to the clinic. 111 
We describe here the use of single-molecule methods to enable the quantitative 112 
characterization of ligand-coupled liposomal drug delivery systems. By removing ensemble 113 
averaging, single-molecule approaches allow the direct visualization of population 114 
distributions and the precise characterization of sub-populations. These methods have already 115 
proven to be important biophysical tools to study a wide variety of biological processes [20-116 
22]. Single-molecule microscopy remains, however, an underutilized technique in 117 
therapeutics development. In this study, we report the quantification of protein attachment to 118 
the surface of single and dual ligand-directed liposomes using single-molecule fluorescence 119 
microscopy. This method allows the detection and quantification of the density of proteins 120 
attached to liposomes, facilitating the characterization and translation of ligand-directed 121 




2. Materials and Methods 124 
2.1. Labeling proteins with fluorophores 125 
Human recombinant plasminogen activator inhibitor-2 (PAI-2, SerpinB2), produced in-house 126 
by previously published methods [23], and trastuzumab (TZ, Herceptin®; Genentech, CA, 127 
USA) were labeled with CF488 or CF647 succinimidyl ester fluorescent dyes (Sigma-128 
Aldrich, MO, USA) as per the manufacturer’s instructions. Absorbance at 280 nm (protein) 129 
and 488 nm or 647 nm (dye) was used to calculate the protein concentration and degree of 130 
labeling (DOL). DOL was further confirmed by electrospray ionization mass spectrometry 131 
(ESI-MS). 132 
2.2. Electrospray ionization mass spectrometry (ESI-MS) 133 
Positive ion mass spectra of unlabeled and labeled proteins were acquired on a quadrupole 134 
time of flight mass spectrometer (Q-TOF-MS) (Micromass Q-TOF Ultima; Waters, MA, 135 
USA) fitted with a Z-spray ionization source. Samples in phosphate-buffered saline (PBS, pH 136 
7.4) were exchanged into deionized water containing 0.1% formic acid and made up to a final 137 
concentration of approximately 10 μM. The mass spectra were acquired with a capillary 138 
voltage of 2.6 kV, cone voltage of 50 V, source block temperature of 40 °C, and a resolution 139 
power of 5000 Hz. Cesium iodide was used for external calibration. Mass was calculated 140 
using MassLynx MS V4.1 (Waters, MA, USA). 141 
2.3. Preparation of liposomes 142 
Liposomes were prepared using the thin film hydration method as described previously [24]. 143 
Dipalmitoylphosphatidylcholine (DPPC), cholesterol, 1,2-distearoyl-sn-glycero-3-144 
phosphoethanolamine-N-[(polyethylene glycol)-2000] (mPEG2000-DSPE) and 1,2-distearoyl-145 
sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (mal-PEG2000-146 
DSPE) (Avanti Polar Lipids, AL, USA) in a 20:10:0.8:0.2 molar ratio (conventional method) 147 
or DPPC, cholesterol and mPEG2000-DSPE in a 20:10:0.6 molar ratio (post-insertion method) 148 
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were dissolved in chloroform/methanol (2:1 v/v). For colocalization experiments, liposomes 149 
were labeled with Octadecyl Rhodamine B Chloride (R18; Invitrogen, CA, USA) by adding 150 
R18 to the chloroform/methanol solution in a 160:1 molar ratio (liposome phospholipid:R18). 151 
Organic solvents were removed by rotary evaporation and subsequent freeze drying to form a 152 
lipid film. Phospholipids were reconstituted in degassed HEPES buffer (115 mM NaCl, 20 153 
mM HEPES, 2.4 mM K2PO4, 1.2 mM CaCl2, 1.2 mM MgCl2; pH 7.4) at a concentration of 154 
20 mM. Once reconstituted, liposomes were passed once through a 0.22 μm PVDF 155 
membrane (Merck Millipore, MA, USA) and then serially extruded 11 times through a 0.1 156 
μm PVDF membrane using a syringe-driven extruding apparatus (Avanti Polar Lipids, AL, 157 
USA) at a temperature of 50°C (above the phase-transition temperature of DPPC). Liposomes 158 
were analyzed by dynamic light scattering to determine particle diameter using a Zetasizer 159 
APS (Malvern Instruments, Malvern, UK). Liposomes were surface-functionalized with 160 
CF647 labeled PAI-2 and/or CF488 labeled PAI-2 or TZ using either the conventional 161 
method or the post-insertion method [25]. For the conventional method, pre-formed 162 
liposomes were incubated with thiolated labeled PAI-2 or TZ (at a molar ratio of 3333:1 163 
liposome phospholipid:protein) for 2 hours at room temperature. For the post-insertion 164 
method, micelles composed of 0.8 mM mal-PEG2000-DSPE and 0.2 mM mPEG2000-DSPE 165 
were prepared as per previously reported methods [26], and labeled PAI-2 or TZ added to the 166 
micelles (at a molar ratio of 10:1, mal-PEG2000-DSPE:protein) to form functionalized 167 
micelles. Functionalized micelles were added to pre-formed liposomes and heated to 60°C for 168 
1 hour to facilitate post-insertion of micelle lipids into the outer leaflet of the liposomes. 169 
Following the liposome functionalization steps, unbound protein was removed from 170 
liposomes via repeated centrifugation at 20,000 x g for 1.5 hours at 4°C. Liposomes were 171 




2.4. Intensity measurements for labeled proteins 174 
Microscope coverslips were thoroughly cleaned to remove any hydrophobic and hydrophilic 175 
contaminants that could cause background fluorescence from the glass. They were first 176 
sonicated for 30 min in ethanol (Chem-Supply, SA, AUS) and then rinsed with deionized 177 
water. Subsequently they were sonicated for 30 min in 1 M potassium hydroxide (KOH; 178 
Sigma-Aldrich, MO, USA) and rinsed with deionized water again. After these sonication 179 
steps were repeated, the coverslips were dried with N2 [27]. CF labeled proteins were diluted 180 
to a concentration of approximately 10 pM and immobilized on the surface of the cleaned 181 
microscope coverslip for visualization on an inverted microscope (Nikon Eclipse Ti-E) with a 182 
CFI Apo Total Internal Reflection Fluorescence (TIRF) 100x oil-immersion TIRF objective 183 
(NA 1.49, Nikon) (Supporting Information Figure S1). The green and red labeled proteins 184 
were excited at 1.5 W cm–2 with 488 nm (Coherent, Sapphire 488-200 CW) and 647 nm 185 
(Coherent, Obis 647-100 CW) lasers, respectively (Supporting Information Figure S1). The 186 
signals were separated via dichroic mirrors (Photometrics, DVΛ Multichannel Imaging 187 
System) and appropriate filter sets (Chroma). The imaging was done with an EMCCD 188 
(Photometics, Evolve 512 Delta). For each measurement, at least two coverslips were used. 189 
For each coverslip, multiple (5–10) fields of view were imaged. Using ImageJ (National 190 
Institutes of Health, USA) with in-house built plugins, we calculated the integrated intensity 191 
for single CF dyes over time, after applying a local background subtraction. Using a change-192 
point step-fitting algorithm, we calculated the intensity distributions for a single CF 193 
fluorophore (Figure 1B) [28, 29]. The histograms obtained were fit with a Gaussian 194 
distribution function using MATLAB 2014b, to give a mean intensity of 2030 ± 40 for the 195 
CF647 (Figure 1C) and 1340 ± 50 for the CF488. To measure the number of fluorophores per 196 
protein, we divided the initial fluorescence intensity per protein by the intensity of a single 197 
fluorophore (Figure 1D, E). 198 
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2.5. Measurement of protein density on liposomes 199 
To find the number of proteins per liposome, we imaged the liposomes under the same 200 
conditions and calculated the fluorescence intensity per liposome analogously. We obtained 201 
the number of proteins per liposome by dividing these intensities by the intensity of a single 202 
protein (Figure 1). 203 
 204 
3. Results and Discussion 205 
To visualize proteins attached to liposomes, we labeled 45 kDa human recombinant 206 
plasminogen activator inhibitor-2 (PAI-2, SerpinB2) with a small red fluorophore (CF647, 207 
0.8 kDa). The degree of labeling (DOL) was determined by visualizing single proteins using 208 
Total Internal Reflection Fluorescence (TIRF) microscopy (Supporting Information Figure 209 
S1). Figure 1A shows a typical field of view of individual labeled PAI-2 proteins 210 
immobilized on a microscope coverslip. TIRF microscopy allows for the selective excitation 211 
of only the fluorescent species on the cover-slip surface and imaging of fluorescence from the 212 
surface-immobilized proteins with high contrast and low background. The intensity of the 213 
signal of every individual protein can be measured over time (Figure 1B, black line). These 214 
intensity trajectories show a stepwise decay towards zero, due to the photobleaching of the 215 
fluorophores on the protein. The height of a single step corresponds to the intensity of a 216 
single fluorophore. Using an unbiased change-point step-fitting algorithm (Figure 1B, red 217 
line) [28], we determined the intensity of a single fluorophore (Figure 1C). By dividing the 218 
total intensity per protein by this single-fluorophore intensity we found that there are 1.47 ± 219 
1.21 fluorophores per protein (Figure 1D), with the width of the distribution in line with that 220 
expected for a Poisson distribution. These values were confirmed by electrospray ionization 221 
mass spectrometry (ESI-MS), which found an average of 3 and up to 6 fluorophores per 222 




Figure 1. Measurement of the number of fluorophores per protein by TIRF microscopy. (A) 225 
Typical field of view – red labeled PAI-2 proteins were immobilized on cleaned coverslips. 226 
(B) Example intensity trajectories of individual labeled proteins (black line). The individual 227 
steps were identified using the change-point algorithm (magenta line) [28, 29]. (C) Histogram 228 
of the intensity of a single CF647 fluorophore, fitted with a Gaussian distribution. The 229 
intensity for a single fluorophore is 3 ± 0.1 ∙ 103 (mean ± s.e.m. N = 962). (D) Histogram of 230 
the number of CF647 fluorophores per protein, fitted with a Poisson distribution. The number 231 
of fluorophores is 1.5 ± 0.4  (mean ± s.d. , N = 291). (E) Histogram of the number of CF488 232 
fluorophores per protein, fitted with a Poisson distribution. This histogram was obtained in 233 
the same way as described for CF647 labeled proteins. The intensity for a single fluorophore 234 
is 1.2 ± 0.6 ∙104 (mean ± s.e.m., N = 796) and the number of fluorophores per protein is 4.5 ± 235 




proteins labeled with a small green fluorophore (CF488, 0.9 kDa) and we obtained an average 238 
of 4.5 ± 2.2 fluorophores per protein (Figure 1E). The reproducibility of this method was 239 
further confirmed using the same batch of protein measured in independent experiments, 240 
where no variation was found between the calculated number. For example, using the PAI-2 241 
protein labeled with CF647 dye, we calculated 1.5 ± 0.4 fluorophores per protein; 4 months 242 
later, we repeated the measurement with same protein, and found 2.0 ± 0.6 fluorophores per 243 
protein (data not shown).  244 
Liposomes functionalized with red labeled PAI-2 were prepared via the post-insertion 245 
method, whereby micelles containing cysteine-reactive poly(ethylene glycol) (maleimide-246 
PEG2000-DSPE) are reacted with protein to form functionalized micelles, before being 247 
incubated with pre-formed liposomes to promote insertion of the protein-PEG2000-DSPE 248 
conjugate into the outer leaflet of the liposome [30]. Liposomes were visualized using TIRF 249 
microscopy under the same conditions that were used to determine the number of 250 
fluorophores per protein. To confirm that the fluorescence signal observed in these 251 
experiments originates from proteins bound to single liposomes, we prepared the liposomes 252 
in the presence of the fluorophore R18 (Octadecyl Rhodamine B Chloride) so that the 253 
encapsulated R18 acts as a marker for only those liposomes that have an intact lipid bilayer 254 
[31]. Using optics that split the image in a yellow and a red channel, the R18 labeled 255 
liposomes and the red labeled proteins were visualized simultaneously but each on different 256 
areas of the camera sensor. Figure 2A represents a typical field of view showing the R18 257 
fluorescence (left), the signal from the red labeled proteins (middle), and a merge of the two 258 
signals (right), with colocalization indicated by white spots. Based on these images, we 259 
calculated that 88% of liposomes have at least one protein attached. Liposomes prepared with 260 
on-maleimide-functionalized micelles were used to confirm that only covalently attached 261 




Figure 2. Visualization of proteins attached to liposomes. (A) Liposomes labeled with R18 264 
(left) and proteins (middle) were imaged simultaneously (N = 14 fields of view, ~30 265 
liposomes per field of view). A merge of the two channels (right) showed a high degree of 266 
colocalization (white spots). (B) Histogram of the number of proteins per liposome, fitted 267 
with a Poisson distribution (black line). The number of proteins is 11 ± 4 (mean ± s.d.) (C) 268 
Histogram of the diameter of the liposomes measured by dynamic light scattering, fitted with 269 
a Gaussian distribution (black line). The diameter is 153 ± 56. Bars represent the mean ± s.d. 270 
(n = 3). 271 
 272 
S3). We then determined the number of proteins per liposome using the fluorescence 273 
intensity from the labeled proteins. We divided this intensity by the intensity of a single 274 
protein, obtained earlier (Figure 1D). We found a density of 11 ± 4 (mean ± s.d.) proteins per 275 
liposome (Figure 2B). Dynamic light scattering revealed a liposome diameter of 153 ± 56 nm 276 
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(mean ± s.d.) and a polydispersity index of 0.041 ± 0.017 (mean ± s.d.) (Figure 2C). If we 277 
calculate the relative width of the distributions in Figures 2B and 2C, we find that this is 0.36 278 
for both distributions. Therefore, we conclude that the width of the distribution of the number 279 
of proteins per liposome correlates with the intrinsic width of the liposome size distribution.  280 
Larger liposomes thus have a greater number of proteins attached than smaller liposomes. 281 
To explore the ability of single-molecule imaging to quantify differences in protein 282 
density, we varied the stoichiometry of two differently labeled proteins and quantified their 283 
ratio on the liposome surface. To negate any potential effects that would arise from using two 284 
different proteins, such as size and reactivity, we used only PAI-2 proteins. Dual-ligand 285 
liposomes were prepared via the post-insertion method, using red and green labeled PAI-2 at 286 
molar ratios of 1:1, 2:1, 5:1 and 10:1, while keeping the total amount of protein added 287 
constant. The two proteins were visualized simultaneously using dual-color imaging (Figure 288 
3A) and the protein density was determined as above. At a 1:1 molar ratio, we found 51 ± 2 289 
% of the total number of proteins per liposome had a red label and 49 ± 2 % had a green label 290 
(Figure 3B). This observation indicates that the fluorophores do not affect protein attachment, 291 
and that the two proteins are incorporated in the same 1:1 ratio as their input stoichiometry in 292 
the formulation process. Further analysis revealed that changing the ratios of the two labeled 293 
proteins during preparation similarly altered the ratios of proteins incorporated into the 294 
liposome (Figure 3C, Supporting Information Figure S4). These results highlight the 295 
accuracy of the single-molecule measurements, and illustrate the ability of this method to 296 





Figure 3. Quantification of the number of proteins per liposome. (A) Typical field of view 300 
showing dual-ligand immobilized liposomes. The green (left) and red dyes (middle) were 301 
visualized simultaneously. When the two channels are merged, colocalized spots show up as 302 
white (right). (B) Histograms of the measured fraction of green and red labeled proteins per 303 
liposome, when equal amounts of each were used during preparation. The fraction of green 304 
labeled proteins is 0.49 ± 0.02 and the fraction of red proteins is 0.51 ± 0.02. (C) Measured 305 
ratio of the fraction of red labeled proteins over the fraction of green labeled proteins as a 306 
function of the molar ratio used during preparation. The errors in the molar ratio are pipetting 307 
errors calculated from the manufacturer-published imprecision ranges of the pipettes used to 308 
add the micelle volumes to the liposomes during preparation. The errors in the measured ratio 309 




Finally, we demonstrated the utility of single-molecule quantification in the 312 
characterization of novel clinically-relevant ligand-directed liposomes. Dual-ligand 313 
liposomes were prepared via both the conventional and the post-insertion methods of 314 
liposome functionalization (Figure 4A). The conventional method involves the incorporation 315 
of polyethylene glycol (PEG) chains with a terminal maleimide functional group (maleimide-316 
PEG-DSPE) into the lipid bilayer of the liposome during formation. Pre-formed liposomes 317 
are then incubated with two different thiolated proteins at 25°C, which attach covalently to 318 
the liposome surface via the maleimide moiety. The post-insertion method involves the 319 
creation of maleimide-PEG-DSPE micelles to which proteins are covalently attached as per 320 
the conventional method. Micelles are then incubated with pre-formed liposomes at a 321 
temperature of 60°C to facilitate the transfer of the micelle PEG-DSPE and attached ligands 322 
into the outer leaflet of the liposome bilayer. In this experiment, PAI-2 and trastuzumab (TZ, 323 
Herceptin®, 145 kDa) were labeled with red and green dyes, respectively, and added to pre-324 
formed liposomes in a 1:1 molar ratio. Imaging and data analysis were performed as outlined 325 
above. Using our single-molecule imaging approach, we determined that the ratio of the PAI-326 
2 and TZ incorporated into liposomes was closer to 1 for liposomes prepared via the post-327 
insertion method (ratio = 2.1 ± 2.5) than for liposomes prepared via the conventional method 328 





Figure 4. Conventional and post-insertion methods for dual-ligand liposome preparation. (A) 332 
In the conventional method, pre-formed liposomes are incubated with two different thiolated 333 
proteins (represented by green and magenta stars), which attach covalently to the liposome 334 
surface via the maleimide moiety. The post-insertion method involves the creation of protein-335 
conjugated micelles, which are then incubated with pre-formed liposomes at a temperature of 336 
60°C to facilitate the transfer of the micelle phospholipids and attached ligands into the outer 337 
leaflet of the liposome bilayer. (B) Comparison of the number of proteins per liposome 338 
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prepared via the conventional and post-insertion methods. When using a 1:1 ratio of 339 
trastuzumab antibody to PAI-2 protein in the conventional preparation method, the number of 340 
PAI-2 proteins per liposome was ~17 times higher than the number of trastuzumab antibodies 341 
(top, N = 115). These numbers were much more similar when the post-insertion method was 342 
used (bottom, N = 167). The black lines represent Poisson distribution fits to the histograms. 343 
Due to the large number of proteins in the top right panel, heterogeneities within the sample 344 
broaden the histogram and obscure the Poisson distribution. This histogram was therefore 345 
fitted with a Gaussian distribution. 346 
 347 
The conventional method involves incubation of a small protein and a large antibody with 348 
pre-formed liposomes, where differences in protein size (i.e. steric hindrance on rates of 349 
reaction) and reactivity (i.e. number of available sites for conjugation) may affect their equal 350 
incorporation into the liposomes. In contrast, the post-insertion method helps negate effects 351 
of these protein differences through the simultaneous insertion of two separate pre-formed 352 
protein-functionalized micelles into the liposomes [25]. These results provide a rationale for 353 
use of the post-insertion method in the production of dual-ligand liposomes functionalized 354 
with two very different proteins in terms of their size and/or reactivity. The application of the 355 
single-molecule quantification informing on the preparation protocol allows for a better 356 
control of the stoichiometry of the liposomes produced. 357 
 358 
4. Conclusion 359 
Herein, we have demonstrated the practical utility of single-molecule fluorescence imaging in 360 
the quantification of the density of protein ligands attached to the surface of liposomes. This 361 
method enables the quantitative characterization of protein densities and the ability to detect 362 
changes therein. While the work presented here explored the quantification of protein and 363 
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whole antibody ligands on the surface of liposomes, the single-molecule approach is also 364 
suitable for quantifying other liposome ligand types, such as antibody fragments, small 365 
peptides and aptamers, provided that they can be fluorescently labeled for single-molecule 366 
imaging. Furthermore, the method permits future experiments to elucidate additional 367 
characteristics of ligand-directed liposomes, including the quantification of inner leaflet and 368 
outer leaflet labeling of liposomes using environmentally (e.g. pH) sensitive dyes [32]. The 369 
use of single-molecule imaging as a quantification technique could improve the 370 
characterization of preclinical ligand-directed liposomes, assist with large-scale 371 
manufacturing processes and allow for batch-to-batch quality control in a commercial 372 
production setting. Using this technique, we showed that the post-insertion method of ligand-373 
coupled liposome preparation is the preferred method for dual-ligand liposomes when using 374 
proteins of different sizes – an aspect relevant to the clinical setting, where liposomes used to 375 
target heterogeneous tumor cell populations would likely bear two different targeting ligands. 376 
By enabling the quantification of surface-bound ligands, and informing on optimal 377 
preparation protocols for ligand-directed liposomes, this single-molecule quantitative 378 
approach is expected to improve the preclinical development of targeted liposomal drug 379 
delivery systems intended for clinic use. 380 
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